menu
    • menu
    [{"orgOrder":0,"company":"QOL Medical","sponsor":"QOL Medical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sucrase","moa":"Sucrase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ QOL Medical","highestDevelopmentStatusID":"8","companyTruncated":"QOL Medical \/ QOL Medical"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Undisclosed"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Undisclosed"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Undisclosed"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Undisclosed"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Partnership","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Optum Frontier Therapies","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Optum Frontier Therapies"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Gastroenterology","graph2":"Phase II","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QOL Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"QOL Medical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by QOL Medical

    Menu

    QOL Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sucraid® Offers Free 4-Day Trial, Only FDA-Approved CSID Therapy

                            Details : Sucraid (sacrosidase) oral solution is indicated for treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency, in adult & pediatric patients 5 months of age & older.

                            Product Name : Sucraid

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 01, 2025

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

                            Details : Sacrosidase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fructan Intolerance.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 27, 2023

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            QOL Medical, LLC Receives FDA Approval of Sucraid® (sacrosidase) Oral Solution Single-Use Containers for Pati...

                            Details : Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

                            Product Name : Sucraid

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

                            Details : Sacrosidase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sucrase-Isomaltase Deficiency, Congenital.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 29, 2022

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Optum Frontier Therapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital ...

                            Details : Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

                            Product Name : Sucraid

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            April 15, 2022

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Optum Frontier Therapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sucrase

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Functional Sucrase Deficiency in Short Bowel Syndrome Patients with Intestinal Failure

                            Details : Sucrase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : Sucrase

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Saf...

                            Details : Sucraid (Sacrosidase) is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sucrase-isomaltase deficiency, congenital.

                            Product Name : Sucraid

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            May 26, 2016

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth